Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
952
-
Total 13F shares, excl. options
-
239M
-
Shares change
-
-3.15M
-
Total reported value, excl. options
-
$56.4B
-
Value change
-
-$908M
-
Put/Call ratio
-
1.32
-
Number of buys
-
486
-
Number of sells
-
-436
-
Price
-
$236.34
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q4 2020
1,128 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q4 2020.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 952 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 239M shares
of 257M outstanding shares and own 93.08% of the company stock.
Largest 10 shareholders include BlackRock Inc. (24.3M shares), VANGUARD GROUP INC (20.4M shares), PRICE T ROWE ASSOCIATES INC /MD/ (19.6M shares), FMR LLC (13.1M shares), STATE STREET CORP (11.4M shares), Capital World Investors (9.65M shares), WELLINGTON MANAGEMENT GROUP LLP (9.21M shares), ALLIANCEBERNSTEIN L.P. (7.94M shares), Capital International Investors (6.69M shares), and Clearbridge Investments, LLC (4.28M shares).
This table shows the top 952 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.